The estimated Net Worth of Roger D Dansey is at least $29.9 Milion dollars as of 15 May 2024. Mr. Dansey owns over 2,166 units of Seagen Inc stock worth over $1,544,576 and over the last 6 years he sold SGEN stock worth over $21,608,159. In addition, he makes $6,718,820 as Chief Medical Officer at Seagen Inc.
Roger has made over 41 trades of the Seagen Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 2,166 units of SGEN stock worth $495,711 on 15 May 2024.
The largest trade he's ever made was selling 34,635 units of Seagen Inc stock on 28 June 2022 worth over $6,234,300. On average, Roger trades about 4,738 units every 31 days since 2018. As of 15 May 2024 he still owns at least 6,749 units of Seagen Inc stock.
You can see the complete history of Mr. Dansey stock trades at the bottom of the page.
Roger Dansey serves as Chief Medical Officer of the Company. Prior to that, Dr. Dansey served as Senior Vice President, Clinical Oncology Research at Merck & Co. from January 2015 through April 2018. While at Merck, Dr. Dansey was Therapeutic Area Head for Late Stage Oncology and was responsible for the ongoing registration efforts for KEYTRUDA® (pembrolizumab) across multiple tumor types. Prior to Merck, from August 2013 to December 2014, Dr. Dansey served as the Vice President, Oncology Clinical Research at Gilead Sciences, Inc. Dr. Dansey previously worked at Amgen in roles of increasing responsibility in Amgen’s oncology and hematology therapeutic areas, including as the Global Development Leader for XGEVA®. Dr. Dansey received his Medical Degrees from the University of Witwatersrand, Johannesburg, South Africa.
As the Chief Medical Officer of Seagen Inc, the total compensation of Roger Dansey at Seagen Inc is $6,718,820. There are 1 executives at Seagen Inc getting paid more, with Clay Siegall having the highest compensation of $14,521,500.
Roger Dansey is 63, he's been the Chief Medical Officer of Seagen Inc since 2018. There are 3 older and 17 younger executives at Seagen Inc. The oldest executive at Seagen Inc is Marc Lippman, 75, who is the Independent Director.
Over the last 22 years, insiders at Seagen Inc have traded over $729,924,224 worth of Seagen Inc stock and bought 35,347,908 units worth $1,433,871,526 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Felixbaker Julian Baker Bro... a Brothers Life Sciences Capi.... On average, Seagen Inc executives and independent directors trade stock every 8 days with the average trade being worth of $18,157,295. The most recent stock trade was executed by David R Epstein on 10 November 2023, trading 10,620 units of SGEN stock currently worth $2,262,166.
seattle genetics, co-founded by clay siegall, is a biotechnology company leading the field of antibody-drug conjugates (adcs) for the treatment of cancer. our technology is designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. our lead program, adcetris® (brentuximab vedotin), is the first in a new class of adcs and, in collaboration with takeda pharmaceutical company limited, is approved in more than 55 countries. to expand on the adcetris opportunity, we are conducting a broad clinical development program to evaluate its therapeutic potential in a range of other lymphoma and non-lymphoma settings. seattle genetics is also advancing a robust pipeline of clinical-stage programs, including sgn-cd19a, sgn-cd33a, sgn-liv1a, sgn-cd70a, asg-22me, asg-15me and sea-cd40. seattle genetics has collaborations for its adc technology with a number of leading biotechnology and pharmaceutical companies, including abbvie, agensys
Seagen Inc executives and other stock owners filed with the SEC include: